Natera Inc Stock Price, News & Analysis

Natera, Inc. (NASDAQ: NTRA) announced a significant change in compensation for its executive leaders and board of directors, who will receive stock instead of cash salaries for the remainder of 2022. This decision reflects their confidence in the company's strong fundamentals and business outlook. Key figures include CEO Steve Chapman, CFO Mike Brophy, and COO Bob Schueren, among others. Natera focuses on cell-free DNA testing across oncology, women's health, and organ health, emphasizing a commitment to personalized diagnostics.

Natera, Inc. (NASDAQ: NTRA) has achieved a significant milestone in its BESPOKE CRC study, enrolling over 1,000 patients across more than 100 sites in the U.S. The study focuses on the impact of Signatera, a custom ctDNA test, in managing colorectal cancer (CRC). Target enrollment is over 2,000 patients, with a follow-up period of up to 5 years. Investigators plan an interim analysis in late 2022. This study aims to provide real-world insights into personalized treatment decisions for CRC patients.

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has announced an investor call on March 10, 2022, to address a recent misleading report by short sellers. CFO Mike Brophy will provide updates and clarify the misinformation. The call will be held at 4:00 a.m. PT (7:00 a.m. ET), with a live dial-in option available for participants. A replay of the webcast will be accessible post-event on Natera's investor relations site. Natera emphasizes its commitment to providing accurate genetic testing validated by extensive peer-reviewed research.

Natera, based in Austin, Texas, responded strongly to a report by Hindenburg Research, labeling it misleading and an attempt by short sellers to profit from negative sentiments. The company emphasizes its commitment to compliance and the efficacy of its testing procedures, supported by over 100 peer-reviewed studies involving more than 1.3 million patients. Natera highlights its high performance in recent studies and maintains an A+ BBB rating, demonstrating a focus on patient satisfaction and operational integrity.

Natera, Inc. (NTRA) reported Q4 2021 revenues of $173.0 million, a 53.9% increase year-over-year, with full-year revenues reaching $625.5 million, up 60%. Product revenues rose 51.1% in Q4, driven by a 48.7% increase in tests processed. However, total operating expenses surged 72.8% in Q4, leading to a net loss of $140.6 million or ($1.48) per share. The company holds $914.5 million in cash, forecasting 2022 revenues between $770 million and $790 million with an approximate gross margin of 46% to 48%.

Natera, Inc. (NASDAQ: NTRA) announced it will release its fourth quarter and year-end 2021 financial results on February 24, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and financial outlook. Natera is a leader in cell-free DNA testing, focused on oncology, women's health, and organ health. Their tests are backed by over 100 peer-reviewed publications, ensuring high accuracy, with operations in Texas and California.

Natera, Inc. (NASDAQ: NTRA) announced the results of a large real-world study confirming the effectiveness of its Prospera donor-derived cell-free DNA (dd-cfDNA) test for kidney transplant patients. Conducted across 33 clinics with 879 patients, the study reported a 64% positive predictive value in detecting active rejection among those with high-risk results. The findings, published in Transplantation Proceedings, indicate that dd-cfDNA testing can enhance physician decision-making in managing transplant patients. This adds to existing evidence supporting the Prospera test's clinical utility.

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, will present updates at several upcoming investor conferences. CEO Steve Chapman and CFO Mike Brophy will speak at:

• 11th Annual SVB Leerink Global Health Care Conference on February 16, 2022, at 1:00 p.m. ET
• Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:50 p.m. ET
• Raymond James 43rd Annual Institutional Investors Conference on March 9, 2022, at 8:40 a.m. ET

Webcasts can be accessed at investor.natera.com.

Natera, Inc. (NASDAQ: NTRA) has announced significant findings from the CIRCULATE-Japan trial concerning its Signatera test for colorectal cancer (CRC). The study involved over 3,000 CRC patients, with key results presented at the ASCO GI 2022 conference. Notably, MRD-positive patients saw substantial benefits from adjuvant chemotherapy, while MRD-negative patients did not. The study also highlighted a 67.6% sensitivity of the Signatera test in detecting cancer recurrences. These results may influence future treatment guidelines for CRC.